Publications by authors named "J F Rivers"
The Restylane® portfolio of hyaluronic acid (HA) fillers comprises a broad range of products, each with a unique combination of gel strength/firmness and flexibility. Restylane® Shaype™ (HASHA) is a new HA injectable produced with NASHA-HD™ technology and the most recent addition to the Restylane portfolio. NASHA-HD is an evolution of the NASHA™ platform that adds more HA and uses a more efficient cross-linking even though the degree of modification is kept low.
View Article and Find Full Text PDFBackground: RelabotulinumtoxinA (RelaBoNT-A) is a complex-free, ready-to-use, liquid botulinum toxin A.
Objective: Efficacy/safety of RelaBoNT-A treatment for lateral canthal lines (LCL).
Methods: Randomized adults received RelaBoNT-A (30 U/side; n = 230) or placebo (n = 73) during a 6-month, double-blind, Ph3 study (Relabotulinumtoxin Aesthetic Development Study-2 [READY-2]).
Article Synopsis
- Presence-absence surveys are often used to track rare species, but their effectiveness for confirming breeding activity needs validation.
- The study focused on the Marbled Murrelet, a threatened seabird in the Pacific, assessing whether these surveys could successfully identify active nesting sites amid difficult conditions.
- Results indicated that while presence-absence surveys may help suggest potential nesting habitats, they are not reliable for pinpointing actual nesting sites, requiring many repeated surveys to accurately assess breeding activity.
We examined the combined effects of neuromuscular electrical stimulation-resistance training (NMES-RT) and functional electrical stimulation-lower extremity cycling (FES-LEC) compared to passive movement training (PMT) and FES-LEC on mitochondrial electron transport chain (ETC) complexes and citrate synthase (CS) in adults with SCI. Thirty-two participants with chronic SCI were randomized to 24 weeks of NMES-RT + FES [n = 16 (14 males and 2 females) with an age range of 20-54 years old] or PMT + FES [n = 16 (12 males and 4 females) with an age range of 21-61 years old]. The NMES-RT + FES group underwent 12 weeks of surface NMES-RT using ankle weights followed by an additional 12 weeks of FES-LEC.
View Article and Find Full Text PDFBackground: OnabotA is used to treat masseter muscle prominence (MMP).
Objective: To assess the safety and efficacy of OnabotA for MMP in a randomized study.
Methods: This 12-month, multicenter, double-blind, placebo-controlled, phase 2 study randomized adults (18-50 years of age) with marked/very marked bilateral MMP (≥4 on the Masseter Muscle Prominence Scale [MMPS]) to OnabotA (24, 48, 72, or 96 U) or placebo; retreatment occurred at day 180 if MMPS ≥4.